These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 30521934)

  • 1. Implication of nigral dopaminergic lesion and repeated L-dopa exposure in neuropsychiatric symptoms of Parkinson's disease.
    Loiodice S; Wing Young H; Rion B; Méot B; Montagne P; Denibaud AS; Viel R; Drieu La Rochelle C
    Behav Brain Res; 2019 Mar; 360():120-127. PubMed ID: 30521934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of L-DOPA on gait abnormalities in a unilateral 6-OHDA rat model of Parkinson's disease.
    Holden H; Venkatesh S; Budrow C; Nezaria S; Coyle M; Centner A; Lipari N; McManus G; Bishop C
    Physiol Behav; 2024 Jul; 281():114563. PubMed ID: 38723388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitrosative and cognitive effects of chronic L-DOPA administration in rats with intra-nigral 6-OHDA lesion.
    Ramírez-García G; Palafox-Sánchez V; Limón ID
    Neuroscience; 2015 Apr; 290():492-508. PubMed ID: 25644418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    Shin E; Rogers JT; Devoto P; Björklund A; Carta M
    Exp Neurol; 2014 Jul; 257():25-38. PubMed ID: 24747357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions.
    Datla KP; Blunt SB; Dexter DT
    Mov Disord; 2001 May; 16(3):424-34. PubMed ID: 11391735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease.
    Ohlin KE; Sebastianutto I; Adkins CE; Lundblad C; Lockman PR; Cenci MA
    Neuroimage; 2012 May; 61(1):228-39. PubMed ID: 22406356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
    Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
    Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
    Yin LL; Geng XC; Zhu XZ
    Brain Res Bull; 2011 Nov; 86(5-6):367-72. PubMed ID: 21963945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
    Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
    Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease.
    Paillé V; Brachet P; Damier P
    Neuroreport; 2004 Mar; 15(3):561-4. PubMed ID: 15094523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic administration of the propargylamine CGP 3466B prevents behavioural and morphological deficits in rats with 6-hydroxydopamine-induced lesions in the substantia nigra.
    Andringa G; van Oosten RV; Unger W; Hafmans TG; Veening J; Stoof JC; Cools AR
    Eur J Neurosci; 2000 Aug; 12(8):3033-43. PubMed ID: 10971644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurokinin B/NK3 receptors exert feedback inhibition on L-DOPA actions in the 6-OHDA lesion rat model of Parkinson's disease.
    Zhang X; Andren PE; Chergui K; Svenningsson P
    Neuropharmacology; 2008 Jun; 54(7):1143-52. PubMed ID: 18423776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. L-DOPA-induced dysregulation of extrastriatal dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson's disease.
    Eskow Jaunarajs KL; George JA; Bishop C
    Neuroscience; 2012 Aug; 218():243-56. PubMed ID: 22659568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
    Kobylecki C; Cenci MA; Crossman AR; Ravenscroft P
    J Neurochem; 2010 Jul; 114(2):499-511. PubMed ID: 20456008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L-Dopa restores striatal dopamine level but fails to reverse MPTP-induced memory deficits in rats.
    Gevaerd MS; Miyoshi E; Silveira R; Canteras NS; Takahashi RN; Da Cunha C
    Int J Neuropsychopharmacol; 2001 Dec; 4(4):361-70. PubMed ID: 11806861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
    Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of chronic, systemic treatment with the dopamine receptor agonist R-apomorphine in partially lesioned rat model of Parkinson's disease: an electrophysiological study of substantia nigra dopamine neurons.
    Gui ZH; Liu J; Wang Y; Ali U; Wang T; Chen L
    Chin J Physiol; 2011 Apr; 54(2):96-104. PubMed ID: 21789890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic L-DOPA treatment attenuates behavioral and biochemical deficits induced by unilateral lactacystin administration into the rat substantia nigra.
    Konieczny J; Czarnecka A; Lenda T; Kamińska K; Lorenc-Koci E
    Behav Brain Res; 2014 Mar; 261():79-88. PubMed ID: 24361083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.